Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Assets (2016 - 2025)

Ironwood Pharmaceuticals' Assets history spans 16 years, with the latest figure at $396.9 million for Q4 2025.

  • For Q4 2025, Assets rose 13.11% year-over-year to $396.9 million; the TTM value through Dec 2025 reached $396.9 million, up 13.11%, while the annual FY2025 figure was $396.9 million, 13.11% up from the prior year.
  • Assets for Q4 2025 was $396.9 million at Ironwood Pharmaceuticals, roughly flat from $396.1 million in the prior quarter.
  • Across five years, Assets topped out at $1.2 billion in Q1 2023 and bottomed at $327.2 million in Q1 2025.
  • The 5-year median for Assets is $561.7 million (2021), against an average of $690.2 million.
  • The largest annual shift saw Assets surged 127.09% in 2021 before it crashed 62.02% in 2024.
  • A 5-year view of Assets shows it stood at $1.1 billion in 2021, then fell by 2.34% to $1.1 billion in 2022, then plummeted by 57.2% to $471.1 million in 2023, then fell by 25.51% to $350.9 million in 2024, then increased by 13.11% to $396.9 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Assets are $396.9 million (Q4 2025), $396.1 million (Q3 2025), and $342.9 million (Q2 2025).